MA39942A - Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2 - Google Patents

Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2

Info

Publication number
MA39942A
MA39942A MA039942A MA39942A MA39942A MA 39942 A MA39942 A MA 39942A MA 039942 A MA039942 A MA 039942A MA 39942 A MA39942 A MA 39942A MA 39942 A MA39942 A MA 39942A
Authority
MA
Morocco
Prior art keywords
radiotherapy
treatment
positive cancers
combination
immuno therapy
Prior art date
Application number
MA039942A
Other languages
English (en)
Inventor
Nicola Mason
Yvonne Paterson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Priority claimed from PCT/US2015/017559 external-priority patent/WO2015130810A2/fr
Priority claimed from US14/669,629 external-priority patent/US10016617B2/en
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MA39942A publication Critical patent/MA39942A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes servant à induire une réponse immunitaire contre une tumeur exprimant l'antigène her-2/neu et à traiter celle-ci et à vacciner contre celle-ci des patients humains et canins par le biais de la combinaison de la radiothérapie et d'un vaccin de souche
MA039942A 2014-05-02 2015-04-02 Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2 MA39942A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
PCT/US2015/017559 WO2015130810A2 (fr) 2014-02-25 2015-02-25 Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu
US14/669,629 US10016617B2 (en) 2009-11-11 2015-03-26 Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers

Publications (1)

Publication Number Publication Date
MA39942A true MA39942A (fr) 2017-03-08

Family

ID=54359144

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039942A MA39942A (fr) 2014-05-02 2015-04-02 Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2

Country Status (11)

Country Link
EP (1) EP3137107A4 (fr)
JP (1) JP2017514904A (fr)
KR (1) KR20170002552A (fr)
CN (1) CN106794234A (fr)
AU (1) AU2015253737A1 (fr)
CA (1) CA2947677A1 (fr)
IL (1) IL248704A0 (fr)
MA (1) MA39942A (fr)
MX (1) MX2016014367A (fr)
SG (1) SG11201609135VA (fr)
WO (1) WO2015167748A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP2683400A4 (fr) 2011-03-11 2014-09-17 Advaxis Adjuvants à base de listeria
SG11201405605VA (en) 2012-03-12 2014-10-30 Advaxis Inc SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
WO2015126921A1 (fr) 2014-02-18 2015-08-27 Advaxis, Inc. Immunothérapie multi-cibles dirigée contre un biomarqueur
WO2015164121A1 (fr) 2014-04-24 2015-10-29 Advaxis, Inc. Souches de listeria utilisées comme vaccin recombinant et procédé de production
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
JP2019521099A (ja) * 2016-06-03 2019-07-25 エトゥビクス コーポレーション Ｈｅｒ２／ｎｅｕを含む、腫瘍ワクチン接種及び免疫療法のための組成物及び方法
SG10202105561PA (en) 2016-11-30 2021-07-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
MX2020003100A (es) 2017-09-19 2020-08-20 Advaxis Inc Composiciones y metodos para la liofilizacion de bacterias o cepas de listeria.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US20050281783A1 (en) * 2003-10-15 2005-12-22 Kinch Michael S Listeria-based EphA2 vaccines
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9084747B2 (en) * 2009-11-11 2015-07-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
WO2011100754A1 (fr) * 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Vaccins à base d'une listeria vivante à titre de thérapie pour le système nerveux central
EP2576791B8 (fr) * 2010-05-23 2016-12-21 Aduro BioTech, Inc. Procédés et compositions utilisant la listeria pour un traitement du cancer par adjuvant

Also Published As

Publication number Publication date
CN106794234A (zh) 2017-05-31
SG11201609135VA (en) 2016-11-29
AU2015253737A1 (en) 2016-12-22
CA2947677A1 (fr) 2015-11-05
EP3137107A4 (fr) 2018-01-17
EP3137107A1 (fr) 2017-03-08
KR20170002552A (ko) 2017-01-06
WO2015167748A1 (fr) 2015-11-05
IL248704A0 (en) 2017-01-31
MX2016014367A (es) 2017-06-30
JP2017514904A (ja) 2017-06-08

Similar Documents

Publication Publication Date Title
MA39942A (fr) Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2
IL280707A (en) Diagnostic and therapeutic methods for treating breast cancer
IL261008B1 (en) Combined immunotherapy and cytokine control therapy for cancer treatment
IL297418B1 (en) Combined immunotherapy and cytokine control therapy for cancer treatment
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
IL272740A (en) Combined immunotherapy and cytokine control therapy for cancer treatment
MX2019011148A (es) Metodos de tratamiento.
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2016011114A (es) Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu.
GEP20217317B (en) Combination therapy for the treatment of cancer
FI3773689T3 (fi) Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
IL279591A (en) Cancer treatment methods using combination therapy
IL281845A (en) Combined treatment for cancer
IL281439A (en) Combined treatment for blood cancer
IL284162A (en) Integrated healing for cancer treatment
IL279277A (en) In vivo controlled combination therapy for treatment of cancer
IL276068A (en) iort device for radiotherapy treatment in cancer patients
EP4037761C0 (fr) Dispositif pour le traitement par radiothérapie de patients atteints d&#39;un cancer
IL275913A (en) Methods and combined treatment for cancer treatment
MX2021001288A (es) Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer.
IL271309A (en) Methods for treating brain tumors through combined therapy